NLRP3 Inflammasome¶
Why it matters in gout¶
NLRP3, ASC, and pro-caspase-1 form an intracellular inflammasome complex. In gout-relevant systems, MSU crystals provide activation inputs that lead to caspase-1 activity, IL-1β maturation, GSDMD cleavage, pyroptosis, and neutrophil-rich inflammation. The pathway is causal enough to supply several intervention nodes, but a downstream cytokine change alone does not identify which node moved.
Open Enzyme chokepoint map¶
The CP labels are an experimental decomposition, not a claim that every candidate acts cleanly at one node.
| Chokepoint | Experimental question | Qualified examples and boundaries |
|---|---|---|
| CP0 — complement-associated priming | Does C5a/C5aR1 or another complement input change the MSU response? | C5a potentiated MSU-associated IL-1β production in human whole blood and primary monocytes in the defined An et al. system (In Vitro; PMID 25229885); related murine work supplies Animal Model evidence. Comparative causal contribution in human flares remains open. |
| CP1a — transcriptional priming | Does the intervention change NF-κB-associated NLRP3 or pro-IL-1β preparation? | Sulforaphane, EGCG, and other exact-material probes have source-specific preclinical evidence; KPV is only a PepT1/priming conjecture without direct MSU evidence |
| CP1b — non-transcriptional priming | Does complement-associated ROS change activation competence without the same transcriptional route? | C5a/ROS work supplies a defined mechanistic branch; tissue and timing must be matched |
| CP2 — NLRP3 activation | Does the intervention change potassium flux, NLRP3 conformation, or NLRP3–NEK7-associated activity? | Oridonin and tranilast have source-specific direct-mechanism evidence; BHB changes potassium-efflux and later assembly readouts but is not a defined direct binder |
| CP3 — ASC assembly | Does ASC oligomerization or speck formation change? | BHB and other exact probes have source-specific preclinical readouts; colchicine affects microtubule-dependent assembly and has clinical gout evidence |
| CP4 — caspase-1 | Is caspase-1 activity or substrate cleavage changed directly? | VX-765 is a direct caspase-1 comparator; downstream caspase readouts do not by themselves establish a direct CP4 mechanism |
| CP5a — IL-1 signaling | Does blocking IL-1 or IL-1R change the gout phenotype? | Product-specific human gout trials establish clinical tractability; exact status and indications require current primary records |
| CP5b — active resolution | Does an exact mediator change termination of MSU inflammation? | Exact RvD1 and MaR1 have distinct MSU mouse evidence; RvD2 is adjacent; EPA/DHA precursors require measured conversion |
| CP6a — neutrophil amplification | Does 5-LOX/LTB4 or another chemotactic input sustain recruitment? | Zileuton and exact natural compounds are separate pharmacology questions; adjacent approval does not establish gout activity |
| CP6b — GSDMD execution | Does the intervention change GSDMD cleavage, pore formation, or pyroptotic release? | Disulfiram and DMF supply exact-mechanism precedents in preclinical systems; gout exposure and efficacy remain separate |
See the NLRP3 exploit map for candidate-level evidence and falsification gates.
Claim discipline¶
- “Direct NLRP3 inhibitor” requires source-verified target-level evidence. Functional IL-1β suppression is not enough.
- A candidate can change several readouts because the cascade is sequential; node count does not rank efficacy.
- Different species, cells, stimuli, assays, and exposure schedules cannot be collapsed into a universal potency ratio.
- A route, dose, combination, or clinical status must come from the exact product and a current primary record.
- Activity in intestinal inflammation does not establish MSU activity or synovial exposure.
Selected exact anchors¶
- BHB: suppressed urate-crystal, ATP, and lipotoxic NLRP3 activation; prevented potassium efflux; reduced ASC oligomerization/specks; and attenuated urate-crystal peritonitis in mice. In Vitro + Animal Model (PMID 25686106). This is pathway regulation, not a defined BHB–NLRP3 binding event.
- Oridonin: exact source-specific covalent NLRP3/NEK7-associated mechanism. In Vitro + Animal Model (PMID 29959312); see oridonin.
- Tranilast: exact source-specific NACHT-domain NLRP3 mechanism. In Vitro (PMID 29531021).
- Dapansutrile: published Phase 2a gout evidence is compound- and protocol-specific. Clinical Trial (PMID 33005902); it does not validate an NLRP3-inhibitor class effect.
- KPV: PepT1-related uptake and an NF-κB reporter result in named non-MSU cell systems. In Vitro (PMID 18061177); direct gout and NLRP3 activity are absent from that experiment.
Reactome boundary¶
The stored Reactome report for R-HSA-844456 is at reference/papers/R-HSA-844456_.pdf. Reactome is curated pathway infrastructure, not primary evidence. The stored report includes P2X7/potassium-efflux, SGT1:HSP90, TXNIP/HMOX1, and pyrin/ASC-associated events. Before proposing a curation addition for BHB, oridonin, tranilast, or another candidate, query the current graph and then verify the load-bearing event against its primary paper.
Cheapest decisive experiment¶
For any new candidate, use one qualified MSU-stimulated human-cell system and measure:
- Exact material identity, free exposure, stability, and viability.
- Priming markers before activation.
- Potassium flux or another candidate-specific upstream event.
- NLRP3/NEK7 or other claimed target engagement.
- ASC oligomerization or specks.
- Caspase-1, GSDMD, IL-1β, and orthogonal inflammasome controls.
Assign the narrowest supported node. If only the final cytokine changes, keep the mechanism unresolved.
Clinical evidence boundary¶
The clinical evidence surface holds selected exact trials and the refresh protocol. It is intentionally not reproduced here. “Approved,” “active,” “terminated,” “first,” “only,” and universal absence claims require a dated primary registry or regulator check.
This is Phase 0 research, not treatment, route, or dosing guidance.